Biomarker for MDS-EB2 diagnosis, detection product and application thereof
CN120847415APending Publication Date: 2025-10-28SHANGHAI UNIV OF T C M
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- CN202510783950.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-06-12
- Publication Date
- 2025-10-28
AI Technical Summary
Technical Problem
Currently, there is a lack of specific bone marrow biomarkers for myelodysplastic syndromes (MDS), especially high-risk MDS-EB2, and existing detection methods do not involve IL-3.
Method used
Interleukin-3 (IL-3) was used as a biomarker for MDS-EB2. The level of IL-3 in bone marrow blood was detected to assist in diagnosis and assessment of drug efficacy, prognosis and treatment effect.
Benefits of technology
As a biomarker for MDS-EB2, IL-3 can significantly improve the relevance of diagnosis and simplify the detection process, providing more accurate diagnostic references and can be used to screen effective therapeutic drugs.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention relates to the field of biotechnology and medicine, and particularly provides IL-3 as a biomarker for diagnosing high-risk myelodysplastic syndrome (MDS EB2 typing). The research finds that the level of IL-3 in bone marrow blood of a patient with the myelodysplastic syndrome (MDS-EB2) is obviously higher than that of a healthy person, so that the IL-3 is used as a biomarker related to diagnosis, treatment and prognosis effects of the MDS-EB2 and is used for diagnosis or auxiliary diagnosis of the myelodysplastic syndrome; the detection reagent can be used for diagnosis and detection of MDS. Detection of the biomarker can provide reference for diagnosis of the high-risk myelodysplastic syndrome MDS-EB2, and the biomarker has a good application prospect.
Need to check novelty before this filing date? Find Prior Art